Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

  • Codony-Servat, Jordi
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Asensio, Elena
  • Montironi, Carla|||0000-0002-1453-2193
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Marín Aguilera, Mercedes
  • Horndler, Carlos
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Rubini, Michele
  • Jares, Pedro
  • Reig, Oscar|||0000-0003-1166-6943
  • Victoria, Iván
  • Gaba, Lydia
  • Martín-Richard, Marta|||0000-0003-4933-2463
  • Alonso Orduña, Vicente|||0000-0003-2280-1004
  • Escudero, Pilar
  • Fernández-Martos, Carlos
  • Feliu, Jaime|||0000-0003-4867-1420
  • Méndez, Jose Carlos
  • Méndez, Miguel
  • Gallego Plazas, Javier|||0000-0002-0584-1242
  • Salud, Antonieta
  • Rojo, Federico|||0000-0001-9989-0290
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Rosell, Rafael|||0000-0003-0817-3400
  • García-Albéniz, Xabier
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Maurel, Joan|||0000-0002-9413-5592
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation. Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R. Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers

  • Torabi Asensio, Keyvan|||0000-0002-9067-0061
  • Erola, Pau
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Milà, Montserrat
  • Lozano, Juan José
  • Miró Ametller, Rosa|||0000-0003-2508-5074
  • Ried, Thomas|||0000-0002-0767-6009
  • Ponsa Arjona, Immaculada|||0000-0003-3436-1907
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatically acquired uniparental disomies (aUPDs) are frequent events in solid tumors and have been associated with cancer-related genes. Studies assessing their functional consequences across several cancer types are therefore necessary. Here, we aimed at integrating aUPD profiles with the mutational status of cancer-related genes in a tumor-type specific manner. Using TCGA datasets for 1,032 gastrointestinal cancers, including colon (COAD), rectum (READ), stomach (STAD), esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), we show a non-random distribution of aUPD, suggesting the existence of a cancer-specific landscape of aUPD events. Our analysis indicates that aUPD acts as a "second hit" in Knudson's model in order to achieve biallelic inactivation of tumor suppressor genes. In particular, APC , ARID1A and NOTCH1 were recurrently inactivated by the presence of homozygous mutation as a consequence of aUPD in COAD and READ, STAD and ESCC, respectively. Furthermore, while TP53 showed inactivation caused by aUPD at chromosome arm 17p across all tumor types, copy number losses at this genomic position were also frequent. By experimental and computationally inferring genome ploidy, we demonstrate that an increased number of aUPD events, both affecting the whole chromosome or segments of it, were present in highly aneuploid genomes compared to near-diploid tumors. Finally, the presence of mosaic UPD was detected at a higher frequency in DNA extracted from peripheral blood lymphocytes of patients with colorectal cancer compared to healthy individuals. In summary, our study defines specific profiles of aUPD in gastrointestinal cancers and provides unequivocal evidence of their relevance in cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetraploidy-associated genetic heterogeneity confers chemo-radiotherapy resistance to colorectal cancer cells

  • Galofré, Claudia|||0000-0003-4415-4987
  • Gönül Geyik, Öykü
  • Asensio, Elena
  • Wangsa, Darawalee
  • Hirsch, Daniela|||0000-0001-8883-922X
  • Parra, Carolina
  • Saez, Jordi|||0000-0003-4888-9323
  • Mollà, Meritxell|||0000-0001-6215-2251
  • Yüce, Zeynep
  • Castells, Antoni|||0000-0001-8431-2033
  • Ried, Thomas|||0000-0002-0767-6009
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, or whole-genome duplication, is a common phenomenon in cancer and preludes chromosome instability, which strongly correlates with disease progression, metastasis, and treatment failure. Therefore, it is reasonable to hypothesize that tetraploidization confers multidrug resistance. Nevertheless, the contribution of whole-genome duplication to chemo-radiotherapy resistance remains unclear. Here, using isogenic diploid and near-tetraploid clones from three colorectal cancer cell lines and one non-transformed human epithelial cell line, we show a consistent growth impairment but a divergent tumorigenic potential of near-tetraploid cells. Next, we assessed the effects of first-line chemotherapeutic drugs, other commonly used agents and ionizing radiation, and found that whole-genome duplication promoted increased chemotherapy resistance and also conferred protection against irradiation. When testing the activation of apoptosis, we observed that tetraploid cells were less prone to caspase 3 activation after treatment with first-line chemotherapeutic agents. Furthermore, we found that pre-treatment with ataxia telangiectasia and Rad3 related (ATR) inhibitors, which targets response to replication stress, significantly enhanced the sensitivity of tetraploid cells to first-line chemotherapeutic agents as well as to ionizing radiation. Our findings provide further insight into how tetraploidy results in greater levels of tolerance to chemo-radiotherapeutic agents and, moreover, we show that ATR inhibitors can sensitize near-tetraploid cells to commonly used chemo-radiotherapy regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Centrosome reduction in newly-generated tetraploid cancer cells obtained by separase depletion

  • Galofré, Claudia|||0000-0003-4415-4987
  • Asensio, Elena
  • Ubach, Maria
  • Torres, Irianna M.
  • Quintanilla, Isabel
  • Castells, Antoni|||0000-0001-8431-2033
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, a common feature in cancer, results in the presence of extra centrosomes, which has been associated with chromosome instability (CIN) and aneuploidy. Deregulation in the number of centrosomes triggers tumorigenesis. However, how supernumerary centrosomes evolve during the emergence of tetraploid cells remains yet to be elucidated. Here, generating tetraploid isogenic clones in colorectal cancer and in non-transformed cells, we show that near-tetraploid clones exhibit a significant increase in the number of centrosomes. Moreover, we find that centrosome area in near-tetraploids is twice as large as in near-diploids. To evaluate whether centrosome clustering was occurring, we next analysed the number of centrioles revealing centriole amplification. Notwithstanding, more than half of the near-tetraploids maintained in culture do not present centrosome aberrations. To test whether cells progressively lost centrioles after becoming near-tetraploid, we transiently transfected diploid cells with siRNA against ESPL1 /Separase, a protease responsible for triggering anaphase, to generate newly near-tetraploid cells. Finally, using this model, we assessed the number of centrioles at different time-points after tetraploidization finding that near-tetraploids rapidly lose centrosomes over time. Taken together, these data demonstrate that although most cells reduce supernumerary centrosomes after tetraploidization, a small fraction retains extra centrioles, potentially resulting in CIN.